Tamoxifen Citrate

• Product NameTamoxifen Citrate
  CAS No.54965-24-1
  Purity99%
  Min QuantityKilograms
  Price0~100
• View Contact Detail

• 
  Molecular Structure

Detailed Description

Tamoxifen Citrate

Quick Details:
--------------------------------------------
Chemical Name: (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxyl]-N,N-dimethyl-ethanamine-citrate;
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene citrate
CAS NO.: 54965-24-1
Molecular Formula: C26H29NO.C6H8O7
Molecular weight: 563.64
Appearance: white crystalline powder
Standard: CP/2000; USP/26

Deacription:
---------------------------------------
Nolvadex (tamoxifen citrate) is used to treat breast cancer that has spread to other parts of the body (metastatic breast cancer), to treat breast cancer in certain patients after surgery and radiation therapy, and to reduce the chances of breast cancer in high-risk patients. Most common side effects include hot flashes, nausea, leg cramps, hair thinning, or headache. A loss of sexual ability/interest may occur in men. Other less common side effects may also occur.

The recommended daily dose of Nolvadex for patients with breast cancer is 20-40 mg per day, in tablet form. Patients taking anastrozole or letrozole should not take Nolvadex as serious interactions could occur. SSRI antidepressants and cimeditdine may affect how Nolvadex works. Patients taking coumarin-type anticoagulants should be closely monitored. There may be risks to the fetus if Nolvadex is taken by pregnant women, however the benefit of the drug may warrant its use despite the potential risks. Nolvadex has been reported to inhibit lactation. It is not known whether the medication is passed through breast milk, but because of the potential risks for the fetus, women who are taking Nolvadex should not breast feed.

SIDE EFFECTS:
---------------------------------------

Adverse reactions to NOLVADEX (tamoxifen citrate) are relatively mild and rarely severe enough to require discontinuation of treatment in breast cancer patients.

Continued clinical studies have resulted in further information which better indicates the incidence of adverse reactions with NOLVADEX (tamoxifen citrate) as compared to placebo.
• 
• Tamoxifen Citrate